A new research paper has been published in Volume 13. oncology science April 2, 2026, titled “Selective Blood-Brain Barrier Penetration and Tumor Targeting of Nitrosylcobalamin in Glioblastoma: Pharmacokinetics, Tissue Distribution, and Synergy with TRAIL and Temozolomide.”
The study was led by first and corresponding author Joseph A. Bauer of Nitric Oxide Services, LLC and Cleveland Clinic Foundation Taussig Cancer Center. In this study, the authors investigated whether nitrosylcobalamin (NO-Cbl), a vitamin B12 analog that releases nitric oxide, can selectively cross the blood-brain barrier (BBB) and target glioblastoma tissue. Glioblastoma multiforme (GBM) remains one of the deadliest and most treatment-resistant brain tumors, with median survival typically less than 15 months despite surgery, radiation, and chemotherapy. One of the biggest obstacles in GBM treatment is the BBB itself, which prevents many anticancer drugs from effectively reaching tumor tissue.
Researchers evaluated NO-Cbl using multiple experimental approaches, including the NCI-60 human tumor cell line panel, pharmacokinetic studies in glioblastoma-bearing rats, and combination therapy experiments in human glioblastoma cell lines. Their findings showed that NO-Cbl exhibits broad antitumor activity across multiple cancer types, while central nervous system tumor cell lines exhibit moderate sensitivity to treatment.
Importantly, in vivo experiments demonstrated that NO-Cbl successfully crosses the BBB and preferentially accumulates within glioblastoma tissue after systemic administration. Tumor nitrate levels remained persistently elevated 24 hours after treatment, whereas normal tissue levels declined more rapidly, supporting selective tumor retention and local nitric oxide delivery within the tumor microenvironment. Figures 2 and 3 (pages 3-4) of this paper further demonstrate the sustained accumulation of nitrate and cobalamin-related metabolites in brain tumor tissue compared to other organs.
This study also investigated whether NO-Cbl could enhance the activity of existing glioblastoma treatments. In cultured U87 and D54 glioblastoma cells, NO-Cbl showed potent synergistic activity when combined with both TRAIL and temozolomide, resulting in greater inhibition of tumor cell proliferation than either treatment alone. Combination index analysis confirmed synergistic interactions across multiple dose ranges.
”This pilot study demonstrates that NO-Cbl crosses the BBB, selectively accumulates in brain tumor tissue, and synergizes with established experimental glioblastoma treatments.. ”
The authors further discuss how NO-Cbl may help overcome some mechanisms of treatment resistance in glioblastoma. Previous studies cited in the paper demonstrated that NO-Cbl can cause apoptosis through activation of caspase-8, inhibit NF-κB survival signaling, and enhance TRAIL receptor signaling through S-nitrosylation. These combined mechanisms may also contribute to improved sensitivity in temozolomide-resistant glioblastoma models.
Importantly, the authors emphasize that this study is a pilot translational study and additional research is still needed before clinical application. Future studies will focus on orthotopic validation, dose optimization, longitudinal nitric oxide tracking, and further mechanistic studies in central nervous system tumor models.
Overall, this study provides initial evidence that cobalamin-based nitric oxide donors may provide a promising new strategy for the treatment of glioblastoma. Combining selective BBB penetration, tumor-targeted nitric oxide delivery, and synergy with existing therapies, NO-Cbl may represent a new platform to improve therapeutic delivery and overcome therapeutic resistance in one of the most challenging cancers in neuro-oncology.
sauce:
Reference magazines:
Bauer JA, others. (2026) Selective blood-brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: pharmacokinetics, tissue distribution, and synergy with TRAIL and temozolomide. oncology science. DOI: 10.18632/oncoscience.654. https://www.oncoscience.us/article/654/
